Eureka Therapeutics is a clinical stage biopharmaceutical company developing novel T-cell therapies that harness the evolutionary power of the immune system with the goal of curing cancer.
The company’s proprietary ARTEMIS™ T-cell receptor technology platform was created to mimic the natural biology of T-cells to fight cancer. Utilizing the ARTEMIS™ platform, we have designed a novel T-cell therapy that is potentially safer and more effective than currently-available T cell therapies.
Our proprietary E-ALPHA® antibody discovery platform comprises one of the world’s largest human-derived high-diversity antibody phage libraries and a robust workflow that allows us to develop highly specific antibodies against target antigens, including peptide-MHC complexes and cell surface proteins.
The company is developing a pipeline of novel cancer therapeutics targeting intracellular oncogenes as well as cell-surface antigens.